NGR-hTNF: Additional Phase II data

Additional data from the open-label, Italian Phase II NGR014 trial in 116 chemotherapy-naïve patients with stage IIIb/IV NSCLC showed that 0.8 µg/m 2 NGR-hTNF every 3 weeks plus cisplatin and pemetrexed or gemcitabine led to a median PFS of 5.8 months vs. 5.7 months for cisplatin and pemetrexed or gemcitabine alone. Additionally, NGR-hTNF plus cisplatin and pemetrexed or gemcitabine produced a response rate of 23% vs. 19% for cisplatin and pemetrexed or gemcitabine alone. One-year OS rates for both treatment groups was 62%. Data will be presented at the American Society of Clinical Oncology meeting in Chicago in June. ...